Biogen Inc. (ETR:IDP)

Biogen Statistics

Total Valuation

Biogen has a market cap or net worth of EUR 23.04 billion. The enterprise value is 25.31 billion.

Market Cap	23.04B
Enterprise Value	25.31B

Important Dates

The next estimated earnings date is Thursday, February 12, 2026.

Earnings Date	Feb 12, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	146.70M
Shares Outstanding	n/a
Shares Change (YoY)	+0.36%
Shares Change (QoQ)	+0.27%
Owned by Insiders (%)	0.17%
Owned by Institutions (%)	91.81%
Float	146.27M

Valuation Ratios

The trailing PE ratio is 16.80 and the forward PE ratio is 13.92.

PE Ratio	16.80
Forward PE	13.92
PS Ratio	2.69
PB Ratio	1.48
P/TBV Ratio	11.33
P/FCF Ratio	11.73
P/OCF Ratio	11.02
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.33, with an EV/FCF ratio of 12.88.

EV / Earnings	18.46
EV / Sales	2.92
EV / EBITDA	8.33
EV / EBIT	11.09
EV / FCF	12.88

Financial Position

The company has a current ratio of 2.72, with a Debt / Equity ratio of 0.36.

Current Ratio	2.72
Quick Ratio	1.77
Debt / Equity	0.36
Debt / EBITDA	1.87
Debt / FCF	2.86
Interest Coverage	10.18

Financial Efficiency

Return on equity (ROE) is 9.31% and return on invested capital (ROIC) is 6.92%.

Return on Equity (ROE)	9.31%
Return on Assets (ROA)	5.75%
Return on Invested Capital (ROIC)	6.92%
Return on Capital Employed (ROCE)	10.21%
Revenue Per Employee	1.13M
Profits Per Employee	180,266
Employee Count	7,605
Asset Turnover	0.35
Inventory Turnover	1.01

Taxes

In the past 12 months, Biogen has paid 251.85 million in taxes.

Income Tax	251.85M
Effective Tax Rate	15.52%

Stock Price Statistics

The stock price has increased by +3.43% in the last 52 weeks. The beta is 0.15, so Biogen's price volatility has been lower than the market average.

Beta (5Y)	0.15
52-Week Price Change	+3.43%
50-Day Moving Average	133.08
200-Day Moving Average	120.61
Relative Strength Index (RSI)	83.75
Average Volume (20 Days)	875

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.39

Income Statement

In the last 12 months, Biogen had revenue of EUR 8.58 billion and earned 1.37 billion in profits. Earnings per share was 9.35.

Revenue	8.58B
Gross Profit	6.57B
Operating Income	2.25B
Pretax Income	1.62B
Net Income	1.37B
EBITDA	2.91B
EBIT	2.25B
Earnings Per Share (EPS)	9.35

Balance Sheet

The company has 3.38 billion in cash and 5.62 billion in debt, giving a net cash position of -2.24 billion.

Cash & Cash Equivalents	3.38B
Total Debt	5.62B
Net Cash	-2.24B
Net Cash Per Share	n/a
Equity (Book Value)	15.52B
Book Value Per Share	105.78
Working Capital	4.81B

Cash Flow

In the last 12 months, operating cash flow was 2.09 billion and capital expenditures -127.16 million, giving a free cash flow of 1.96 billion.

Operating Cash Flow	2.09B
Capital Expenditures	-127.16M
Free Cash Flow	1.96B
FCF Per Share	n/a

Margins

Gross margin is 76.56%, with operating and profit margins of 26.28% and 15.98%.

Gross Margin	76.56%
Operating Margin	26.28%
Pretax Margin	18.92%
Profit Margin	15.98%
EBITDA Margin	33.87%
EBIT Margin	26.28%
FCF Margin	22.89%

Dividends & Yields

Biogen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.36%
Shareholder Yield	-0.36%
Earnings Yield	5.95%
FCF Yield	8.53%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on January 18, 2001. It was a forward split with a ratio of 3.

Last Split Date	Jan 18, 2001
Split Type	Forward
Split Ratio	3

Scores

Biogen has an Altman Z-Score of 3 and a Piotroski F-Score of 6.

Altman Z-Score	3
Piotroski F-Score	6